Aptar Pharma, a global provider of drug delivery and active material science solutions and services, has announced a collaboration with TFF Pharmaceuticals to develop and test the administration of dry powder vaccines utilizing TFF’s thin film freezing technology and Aptar’s proprietary intranasal unidose (UDS) powder nasal spray system.
TFF is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented thin film freezing technology platform, which has broad applicability to convert drugs and vaccines into a dry powder formulation for local administration.
A need for alternative routes of vaccination, such as intranasal, was highlighted at the White House Summit on the Future of Covid-19 vaccines, which took place in July 2022. The development of an effective intranasal vaccine has numerous potential advantages over conventional, subcutaneous, or intramuscular-based delivery.
First, the nasal passageway is very often the first point of entry for certain pathogens. So if the pathogen can be halted in the nasal passages, curtailing the spread of infection further, this could lead to an improved overall prognosis. In addition, the direct immunization of nasal mucosa may promote systemic and mucosal immunity, which may help prevent viral shedding and disease transmission.
Furthermore, the self-administration of a nasal powder vaccine provides for “needle-free” administration to the patient and avoids the need for syringe disposal, and potentially simplifies global distribution with the elimination of extreme cold from the supply chain. These aspects of nasal delivery could open up vaccine availability to larger populations in regions and countries with limited refrigeration infrastructure.
During the Vaccines Summit-2022, which took place from 11 to 13 October 2022, in Washington, Aptar presented research findings from their collaboration with TFF Pharmaceuticals. The presentation highlighted data related to the nasal deposition of a dry powder vaccine, the physical characteristics of the administered formulation, the integrity and activity testing of the dry powder vaccine after administration, and the emitted particle size. The amount of dry powder delivered to the targeted region of the nasal cavity was also presented. Aptar will present additional data on these efforts at the World Vaccine & Immunotherapy Congress in San Diego from 28 November to December 1, 2022.
“We are very excited to partner with Aptar Pharma to test our thin film freezing formulation with their unique intranasal device,” said Glenn Mattes, president & CEO of TFF Pharmaceuticals. “By combining our collective and proprietary expertise in drug development, device engineering, and formulation technologies, we believe this collaboration has the potential to create ground-breaking advancements in the field of drug delivery. Intranasal dry powder vaccines could be a true game changer for people around the world.”
“The nasal vaccine formulation developed using TFF’s technology combines the antigen and adjuvant into one ready-to-use device,” said Dr Julie D. Suman, vice-president, Scientific Affairs at Aptar Pharma. “This eliminates the need for combining separate vials, which potentially saves time, reduces human error and medical waste.”
The results of the feasibility testing will be published by Aptar Pharma, The University of Texas at Austin (UT) and TFF Pharmaceuticals in the coming months. Aptar, UT, and TFF have summarized the results of the initial intranasal vaccine feasibility testing in a preprint publication, to be followed by a peer-reviewed publication in the coming months.
